Patient Advocacy and Research Organization
Appears in 1 story
Celebrated generic availability while crediting Vertex research
A generic version of Trikafta—the breakthrough cystic fibrosis drug that extends lives by decades—hit the market at $12,750 per year. That's 95% cheaper than Vertex Pharmaceuticals' brand-name version, which costs over $300,000 annually and has generated billions while remaining out of reach for patients in developing nations and many Americans with inadequate insurance.
Updated Jan 12
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
